Clinical Report: Facial Rehabilitation for Depression: Results from a Randomized Controlled Trial of the FaReWell Program

Overview

The FaReWell program, a facial rehabilitation intervention, demonstrated significant reductions in depression severity among participants compared to a control group. This study provides preliminary evidence supporting the use of facial physiotherapy as a novel approach to managing depression.

Background

Facial feedback mechanisms play a crucial role in modulating emotional states, with implications for treating depression. Traditional treatments primarily focus on pharmacotherapy and psychotherapy, leaving a gap for innovative non-pharmacological interventions. The FaReWell program aims to leverage facial muscle rehabilitation to enhance emotional wellbeing in individuals with depression.

Data Highlights

Key Findings

• The FaReWell program significantly reduced MADRS scores in the intervention group compared to the control group.
• There was a significant group × time interaction effect (F = 6.37, p = .017).
• Secondary outcomes, including anhedonia and facial self-perception, did not show significant differences over time.
• Participants engaged in daily 15-minute sessions of facial rehabilitation.
• The study involved 49 patients with mild to moderate depression.

Clinical Implications

The findings suggest that facial physiotherapy may serve as a complementary intervention for patients with mild to moderate depression. Clinicians should consider exploring non-pharmacological approaches like the FaReWell program as adjuncts to traditional treatments.

Conclusion

The FaReWell program shows promise as a novel therapeutic approach for depression, warranting further investigation to establish its efficacy and potential integration into treatment protocols.

Related Resources & Content

1. BMC Psychiatry (Springer), 2025 -- Evaluation of a pro-recovery training intervention (REFOCUS-RETAFORM) in specialist mental health services across France: stepped-wedge cluster randomised controlled trial protocol
2. Journal of Neuro-Oncology, 2021 -- Digital Cognitive Rehabilitation for Patients with Brain Tumors: Findings from a Randomized Controlled Study
3. BMC Psychiatry (Springer), 2025 -- Exploring the Efficacy of Virtual Reality Therapy in Treating Depression Among Adolescents: A Prospective Observational Analysis
4. Overview | Depression in adults: treatment and management | Guidance | NICE, 2026
5. Efficacy and Safety of Botulinum Toxin vs. Placebo in Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials - PMC
6. BMC Psychiatry (Springer) — Evaluating the Effectiveness of Computer-Assisted Cognitive Remediation (CACR) for Schizophrenia: Results from a Randomized Controlled Trial
7. Overview | Depression in adults: treatment and management | Guidance | NICE
8. Efficacy and Safety of Botulinum Toxin vs. Placebo in Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials - PMC
9. These highlights do not include all the information needed to use BOTOX Cosmetic safely and effectively. See full prescribing information for BOTOX Cosmetic.     BOTOX ® Cosmetic (onabotulinumtoxinA) for injection, for intramuscular use Initial U.S. Approval: 1989